Despite a considerable patient population, the angina pectoris market has long been overlooked by drug developers, with only one antianginal having entered the market in the US in more than a decade. The current treatment paradigm consists mostly of well-established generic drug and drug classes, yet more recently, clinical development activity in the space has picked up in certain markets with more companies attempting to apply innovative approaches to fulfill the unmet needs that remain.
In this webinar, the angina pectoris market (defined as the chronic angina types: stable, microvascular and variant) is analysed over the course of a 10-year period from 2018–2028, in seven major pharmaceutical markets US, 5EU (France, Germany, Italy, Spain, UK) and Japan. Both marketed and pipeline therapies will be discussed, and GlobalData’s primary research will shed light on current physician insight into this market. The webinar will also highlight some the major unmet needs in the space and remaining opportunities in the market.
In this expert presentation, Kelly Lambrinos, Senior Analyst at GlobalData will present on current and future trends shaping the angina pectoris market, drawing on insights from GlobalData’s report, Angina Pectoris: Global Drug Forecast and Market Analysis to 2028. The webinar combines KOL insights along with in-house analyst expertise to provide a competitive assessment of the marketplace.
Jesse Cuaron, Associate Director of CVMD and Gender Health at GlobalData, will moderate a Q&A session following the presentation.
Presented by
Kelly Lambrinos,
Senior Healthcare Analyst at GlobalData
Kelly Lambrinos, MA, is a Senior Analyst for Cardiovascular and Metabolic Disorders and Gender Health. Kelly has several years of experience as analyst conducting research on the pharmaceutical and biotechnology industry. Prior to GlobalData, Kelly worked at a boutique regulatory consulting firm, where she provided scientific and regulatory support for major pharmaceutical and biotechnology companies. Kelly holds a Bachelor’s degree in Biology from the University of Athens, Greece and a MA in Biotechnology from Columbia University.
Jesse Cuaron,
Associate Director of CVMD and Gender Health at GlobalData
Jesse Cuaron, PhD, PPM, is an Associate Director in the area of CVMD and Gender Health at GlobalData. His core responsibilities include providing expert insight on the pharmaceutical industry and contributing to the scope and direction of high quality CVMD and Gender Health market analysis deliverables. Prior to GlobalData, Jesse worked on projects as a Project Manager with Pfizer, Aemetis Inc., and the University of California, Riverside during his completion of a Postdoctoral Professional Masters (PPM) in Bioscience Management (Keck Graduate Institute of Applied Life Sciences, Claremont Colleges). Jesse received his PhD and BSc in Biology, Microbiology, and Molecular Biology at New Mexico State University. His research involved the identification of factors that Staphylococcus aureus requires to express reduced susceptibility to vancomycin, ethanol, and tea tree oil.
